Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00685165
Other study ID # 04090
Secondary ID
Status Completed
Phase Phase 1
First received May 24, 2008
Last updated December 16, 2009
Start date May 2004
Est. completion date June 2004

Study information

Verified date November 2009
Source Mutual Pharmaceutical Company, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline®(primidone tablets) in adult subjects under fasting conditions.


Description:

The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline® (primidone tablets) in adult subjects under fasting conditions.

Twenty-two healthy, non-smoking, non-obese male and female volunteers at least 18 years of age will be randomly assigned in a crossover fashion to receive each of two primidone dosing regimens in sequence with a 14 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, primidone (1 x 50 mg tablet) or a single oral dose of the reference formulation, Mysoline® (1 x 50 mg tablet). After a 14 day washout period, on the morning of Day 15 after an overnight fast, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 72 hours post dose at times sufficient to adequately define the pharmacokinetics of primidone. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drugs and/or procedures. Blood pressure and heart rate will be obtained prior to dosing and at 3, 4, 6, 24 and 72 hours post-dose. All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date June 2004
Est. primary completion date June 2004
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- male or female

- at least 18 years of age

- weight must be 15% of ideal weight for height and frame

- subjects must be in good health and physical condition as determined by medical history

- subjects must read and sign consent form

Exclusion Criteria:

- history of treatment for alcoholism, substance abuse, or drug abuse within the last 24 months

- history of malignancy, stroke, diabetes, cardiac, renal or liver disease

- history of gastroesophageal reflux disease (GERD), malabsorption syndrome, colon cancer, chronic colitis, including Crohn's disease

- history of porphyria, hyperkinesia, respiratory diseases (eg. asthma, emphysema, difficulty breathing, pulmonary obstruction)

- females who pregnant or lactating

- history of hypersensitivity to primidone, barbiturates, and anticonvulsants

- sitting systolic blood pressure below 90mm Hg, or diastolic pressure below 50mm Hg (conditions upon screening which might contraindicate or require that caution be used in the administration of primidone)

- heart rate less than 50 beats per minute after a 5 minute rest

- treatment with any other investigational drug during the four weeks prior to initial dosing

- subjects who have donated blood within four weeks prior to the initial dosing

- subjects who smoke or use tobacco products or nicotine products. Three months abstinence is required.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Primidone 50 mg Tablet
50 mg tablet administered after an overnight fast of at least 10 hours.
Primidone (Mysoline®) 50 mg Tablet
50 mg tablet administered after an overnight fast of at least 10 hours.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mutual Pharmaceutical Company, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Plasma Concentration (Cmax) serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration. No
Primary Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration. No
Primary Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-8)] serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 18, 24, 36, 48, 60 and 72 hours after drug administration. No
See also
  Status Clinical Trial Phase
Completed NCT04467346 - Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules Phase 1
Completed NCT00807118 - Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect Phase 1
Withdrawn NCT01405170 - A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions Phase 1
Completed NCT04885660 - Bioequivalence Evaluation of Two Fixed-dose Combination of Lisinopril 10mg/Levamlodipine Besylate 5mg in Healthy Chinese Subjects Phase 1
Completed NCT05786339 - Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects Phase 1
Completed NCT00709189 - Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women. Phase 1
Completed NCT00658541 - Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets Phase 1
Completed NCT00997789 - Bioequivalence of Rebamipide in Korean N/A
Completed NCT00684762 - Fasted Bioavailability Study of Cilostazol Tablets, 100 mg Phase 1
Recruiting NCT04814589 - Bioequivalence of Ezetimibe Tablets in Healthy Subjects Phase 1
Completed NCT03631316 - Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir N/A
Recruiting NCT04438720 - Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects Phase 1
Completed NCT01359163 - A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects Phase 1
Completed NCT00650221 - Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects Phase 1
Completed NCT00648544 - Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects Phase 1
Completed NCT05225974 - A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects Phase 1
Withdrawn NCT01405157 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions Phase 1
Withdrawn NCT01405131 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Phase 1
Completed NCT05282940 - Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product Phase 1
Completed NCT06050343 - Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method N/A